In this post hoc analysis of data from the REWIND trial, dulaglutide use was not linked with a decreased incidence of atrial arrhythmias (AA) in this at-risk group of patients with type 2 diabetes.

• A total of 9,543 patients (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without ECG-confirmed AA at baseline, and randomized in the REWIND trial, were analyzed to assess the occurrence of atrial fibrillation or atrial flutter in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide vs placebo.

• A median 5.4 years of follow-up revealed the occurrence of at least one episode of AA in 524 patients (5.5%).

• Incident AA occurrence was evident in 5.6% of the patients who received dulaglutide, at a rate of 10.7 per 1,000 person-years, vs in 5.3% of those treated with placebo, at a rate of 10.5 per 1000 person-years.

• Dulaglutide did not impact the composite outcome of AA and death or AA and heart failure.